ICMR seeks to provide oral formulation of hydroxyurea to treat sickle cell disease in children

The biggest challenge in treatment is that hydroxyurea, which is marketed as 500 mg capsules or 200 mg tablets, is not available in the suspension form for effective use in the case of paediatric patients, the ICMR said The biggest challenge in treatment is that hydroxyurea, which is marketed as 500 mg capsules or 200 mg tablets, is not available in the suspension form for effective use in the case of paediatric patients, the ICMR said Health Health News, Wellbeing Tips, Diseases, Treatment and Nutrition | The Hindu